Skip to content

Author

B. Rengarajan

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Real-world effectiveness and safety of lurbinectedin in previously treated small cell lung cancer: results from Jazz EMERGE 402.

BACKGROUND In extensive-stage small cell lung cancer (ES-SCLC), lurbinectedin is approved for first-line maintenance treatment with atezolizumab and as monotherapy following disease progression, but prospective real-world data on its use are lacking. METHODS Jazz EMERGE 402 was a prospective, observational, phase 4 t...

F. Badin, Philip E. Lammers, Geoffrey Liu et al. · 0 citations
Open access Oct 2026

Healthcare resource utilization and costs of US patients with small cell lung cancer treated with second-line therapies: a retrospective real-world database study.

AIMS To examine all-cause and myelosuppressive event (MYSPE)-related healthcare resource utilization and costs among patients with small cell lung cancer (SCLC) in the United States treated with second-line therapies. MATERIALS AND METHODS This retrospective cohort study of the Optum Market Clarity database included...

X. Fan, A. Nguyen, B. Rengarajan et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.